Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
This was at the high-end of the Roger ?Perlmutter-led company's targeted range of $16 to $18 a share. The offering comes as IPO activity shows signs of picking up in 2026, following a government shutdown in October of the ?previous year that ?forced many companies to delay their listing plans. Biotech offerings are also seeing a resurgence ?early this year, with drug developers including SpyGlass Pharma and AgomAb Therapeutics filing for U.S. listings in January. Eikon was founded ?in 2019 by Chemistry Nobel Prize winner Eric ?Betzig, along with Xavier Darzacq, Luke Lavis and Robert Tjian, and is developing a pipeline of experimental treatments for cancer. Its most advanced drug candidate, EIK1001, is being tested in combination with Merck's Keytruda in a mid-to-late ?stage trial for a form ?of skin cancer. The company ?expects an interim analysis from the study in the second half of 2026. The company's shares ?will start trading ?on the Nasdaq under the ticker symbol "EIKN
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks” [Yahoo! Finance]Yahoo! Finance
- Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda [FOX Business Network]FOX Business Network
- Where is Merck & Co. (MRK) Headed According to Wall Street? [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Citigroup Inc. from $115.00 to $120.00. They now have a "neutral" rating on the stock.MarketBeat
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- MRK's page on the SEC website